Join the club for FREE to access the whole archive and other member benefits.

YouthBio Therapeutics

Developing rejuvenation gene therapies based on partial reprogramming by Yamanaka factors

Pioneering tissue-specific gene therapies to rejuvenate tissues, improve organ function and, ultimately, delay aging.

At YouthBio, our mission is to harness the power of cellular reprogramming to restore a more youthful gene expression profile in targeted cells, leading to positive therapeutic effects in corresponding organs. Our ultimate goal is achieving systemic rejuvenation by targeting multiple key organ systems via tailored therapies. To get there, we are first starting with single-organ therapies aimed at existing diseases.

Discover the incredible potential of partial reprogramming to revolutionize the way we combat and prevent age-related diseases, and ultimately delay or possibly even reverse aging.

YouthBio Therapeutics Executive Team

  • Yuri Deigin - Co-founder and Director
  • Viet Ly - Co-founder and CFO
  • João Pedro de Magalhães - Chief Scientific Officer
  • Alejandro Ocampo - Lead Research Collaborator
  • Stephanie Chang - CFO

Visit website:


Details last updated 02-Apr-2022

Mentioned in this Resource

Alejandro Ocampo

Assistant Professor at University of Lausanne

João Pedro de Magalhães

Professor of Molecular Biogerontology at University of Birmingham Institute of Inflammation and Ageing, consultant, futurist, speaker

Stephanie Chang

Chief Financial Officer at YouthBio Therapeutics

Viet Ly

Co-founder and CFO at YouthBio Therapeutics and General Partner/ Fund Manager at Inception Capital

Yuri Deigin

Co-founder and Director at YouthBio Therapeutics

YouthBio Therapeutics News

Unveiling the future of age reversal: meet Yuri Deigin, founder of YouthBio Therapeutics

Longevity Technology - 08-Mar-2023

Tissue-specific gene therapies & rejuvenating factors to extend lifespan and combat age-related diseases


Reason reports back from October's Rejuvenation Startup Summit

Fight Aging! - 19-Oct-2022

Some really exciting developments with quite a few in clinical trials

Read more... interviews João Pedro de Magalhães about theories of, and curing, ageing (LEAF) - 13-May-2022

The one thing I hope he's wrong about is that it won't happen in his lifetime - we just need some exponential oomph!


YouthBio Therapeutics unveils its board, with João Pedro de Magalhães as CSO

CISION PR Newswire - 14-Apr-2022

Another company enters the cellular reprogramming race - hopefully at least one will cross the finishing line

Topics mentioned on this page:
Gene Therapy, Rejuvenation